Kenneth Getz, MBA

Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.

New research sheds fresh light on a trend with serious consequences for the public health-not only in the United States but for patients worldwide.

Sponsor sourcing requirements are diverging from the operating needs and long-term strategies of the major CROs.

Big Pharma is finally making a commitment to partner-based outsourcing.